Mitsubishi UFJ Trust & Banking Corp Sells 137,164 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Mitsubishi UFJ Trust & Banking Corp reduced its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 6.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,869,142 shares of the biopharmaceutical company's stock after selling 137,164 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.32% of Royalty Pharma worth $47,682,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in RPRX. Advisors Asset Management Inc. acquired a new stake in Royalty Pharma during the 3rd quarter valued at $359,000. Charles Schwab Investment Management Inc. raised its position in shares of Royalty Pharma by 58.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company's stock valued at $84,915,000 after purchasing an additional 1,103,341 shares during the period. Raymond James Trust N.A. boosted its holdings in shares of Royalty Pharma by 108.5% during the 3rd quarter. Raymond James Trust N.A. now owns 24,858 shares of the biopharmaceutical company's stock worth $703,000 after buying an additional 12,936 shares during the period. Cerity Partners LLC grew its stake in Royalty Pharma by 11.1% in the 3rd quarter. Cerity Partners LLC now owns 32,896 shares of the biopharmaceutical company's stock valued at $931,000 after buying an additional 3,291 shares during the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in Royalty Pharma by 10.8% in the 3rd quarter. Daiwa Securities Group Inc. now owns 30,694 shares of the biopharmaceutical company's stock valued at $868,000 after acquiring an additional 3,000 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Royalty Pharma Price Performance

Shares of NASDAQ RPRX traded down $0.28 during mid-day trading on Friday, reaching $31.37. The company had a trading volume of 4,077,104 shares, compared to its average volume of 3,103,202. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The firm has a market cap of $18.08 billion, a price-to-earnings ratio of 21.63, a PEG ratio of 2.31 and a beta of 0.47. The business's 50-day simple moving average is $32.44 and its 200 day simple moving average is $28.85.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, research analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date was Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.81%. This is a boost from Royalty Pharma's previous quarterly dividend of $0.21. Royalty Pharma's payout ratio is 60.69%.

Analyst Ratings Changes

Several research firms have recently commented on RPRX. Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.